
Neway and Quest Diagnostics Partner to Improve Dialysis Patient Care
Neway, LLC, a provider of value-based dialysis lab care in the United States, has announced a strategic lab services partnership with Quest Diagnostics (NYSE: DGX). The collaboration is designed to streamline dialysis laboratory testing and reduce associated costs for patients with end-stage renal disease (ESRD).
The agreement outlines Neway’s use of Quest Diagnostics’ extensive lab network to offer local dialysis laboratory testing services, with the goal of providing test results typically within one day of arrival at a Quest Diagnostics laboratory. This partnership seeks to provide an alternative to the prevailing centralized lab model, where the majority of U.S. dialysis programs transport specimens to a single laboratory for processing. By leveraging Quest’s distributed lab network, Neway and its affiliated dialysis centers aim to offer faster testing and results reporting while also reducing transportation expenses.
Neway’s focuses on dialysis patient management with a primary goal is to provide faster diagnostic services to dialysis patients to improve outcomes through better patient management. Quest’s extensive laboratory logistics network and specialty testing services enable this partnership.
Bryan Thompson, Founder and CEO of Neway, emphasized the commitment to bringing innovation and cost-efficiency to the dialysis industry. He noted that the centralized model, in use since the early 1990s, lacks innovation and is costly and time-consuming. In contrast, the decentralized network of laboratory locations spanning the nation is expected to benefit dialysis patients, programs, insurance providers, and the entire dialysis sector.